These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7123181)

  • 1. [Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population].
    Dick B; Küpfer A; Molnàr J; Braunschweig S; Preisig R
    Schweiz Med Wochenschr; 1982 Jul; 112(30):1061-7. PubMed ID: 7123181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.
    Du YL; Lou YQ
    Zhongguo Yao Li Xue Bao; 1990 Jan; 11(1):7-10. PubMed ID: 2403020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology.
    Pollock BG; Perel JM; Altieri LP; Kirshner M; Fasiczka AL; Houck PR; Reynolds CF
    Psychopharmacol Bull; 1992; 28(2):163-8. PubMed ID: 1513919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine.
    Leclercq V; Desager JP; Horsmans Y; Van Nieuwenhuyze Y; Harvengt C
    Int J Clin Pharmacol Ther Toxicol; 1989 Dec; 27(12):593-8. PubMed ID: 2613393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effects of neuroleptics on debrisoquine oxidation in man.
    Syvälahti EK; Lindberg R; Kallio J; De Vocht M
    Br J Clin Pharmacol; 1986 Jul; 22(1):89-92. PubMed ID: 2874826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Debrisoquine hydroxylation phenotypes of patients with high versus low to normal serum antidepressant concentrations.
    Tacke U; Leinonen E; Lillsunde P; Seppälä T; Arvela P; Pelkonen O; Ylitalo P
    J Clin Psychopharmacol; 1992 Aug; 12(4):262-7. PubMed ID: 1527229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk.
    Caporaso N; Pickle LW; Bale S; Ayesh R; Hetzel M; Idle J
    Genet Epidemiol; 1989; 6(4):517-24. PubMed ID: 2777072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of subclinical perhexiline neuropathy in a patient with inborn error of debrisoquine hydroxylation.
    Shah RR; Oates NS; Idle JR; Smith RL; Lockhart JD
    Am Heart J; 1983 Jan; 105(1):159-61. PubMed ID: 6295127
    [No Abstract]   [Full Text] [Related]  

  • 9. Polymorphic drug oxidation in humans.
    Eichelbaum M
    Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation.
    Sloan TP; Idle JR; Smith RL
    Clin Pharmacol Ther; 1981 Apr; 29(4):493-7. PubMed ID: 7471615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation.
    Yue QY; Svensson JO; Alm C; Sjöqvist F; Säwe J
    Br J Clin Pharmacol; 1989 Dec; 28(6):639-45. PubMed ID: 2611086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
    Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
    J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
    Kallio J; Lindberg R; Huupponen R; Iisalo E
    Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.
    Mellström B; Bertilsson L; Säwe J; Schulz HU; Sjöqvist F
    Clin Pharmacol Ther; 1981 Aug; 30(2):189-93. PubMed ID: 7249504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects.
    Steiner E; Bertilsson L; Säwe J; Bertling I; Sjöqvist F
    Clin Pharmacol Ther; 1988 Oct; 44(4):431-5. PubMed ID: 3168394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.
    Nakamura K; Goto F; Ray WA; McAllister CB; Jacqz E; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1985 Oct; 38(4):402-8. PubMed ID: 4042523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphic hydroxylation of Debrisoquine in man.
    Mahgoub A; Idle JR; Dring LG; Lancaster R; Smith RL
    Lancet; 1977 Sep; 2(8038):584-6. PubMed ID: 71400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacogenetics of antidepressant metabolism. Value of the debrisoquin test].
    Baumann P
    Encephale; 1986; 12(4):143-8. PubMed ID: 3792273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetically determined oxidation capacity and the disposition of debrisoquine.
    Sloan TP; Lancaster R; Shah RR; Idle JR; Smith RL
    Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.